BiotechTube

Nivolumab + Topotecan + Amrubicin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lung Cancer

Conditions

Lung Cancer

Trial Timeline

Sep 14, 2015 → Aug 30, 2022

NCT ID
NCT02481830

About Nivolumab + Topotecan + Amrubicin

Nivolumab + Topotecan + Amrubicin is a phase 3 stage product being developed by Ono Pharmaceutical for Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02481830. Target conditions include Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Lung Cancer were approved

Approved (20) Terminated (3) Active (0)
✅Sivelestat sodium hydrate + Sivelestat sodium hydrateOno PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Budesonide + SymbicortAstraZenecaApproved
✅Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ugAstraZenecaApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02481830Phase 3Completed

Competing Products

20 competing products in Lung Cancer

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39